



ASX & Media Release

## September 2016 Appendix 4C

**Melbourne, Australia; October 28, 2016:** Patrys Limited (**ASX: PAB**) is pleased to lodge its Appendix 4C for the quarter ended 30 September 2016.

### Finance

The Company held cash reserves of \$3.013 million at the end of September, with net cash outflows from operations during the quarter of \$0.136 million.

During the quarter the Company reached an agreement regarding amounts due from a contracting party and received \$0.334 million, with additional funds expected to be released to the Company from escrow this year.

### Operations

During the quarter, Patrys completed *in silico* biology to optimise Deoxymab 3E10, and entered into a sponsored research agreement with Yale University to complete lead candidate selection and pre-clinical testing of this new asset originally invented at Yale University, New Haven, Connecticut, USA.

Deoxymab 3E10 is a novel autoantibody that has the capacity to penetrate cancer cell nuclei, damage DNA, inhibit DNA repair, and kill DNA repair-deficient cancer cells.

Patrys' Chinese license partner for PAT-SC1, Hefei Co-source Biomedical, is successfully pursuing development activities with PAT-SC1. Patrys maintains an active program to resolve the manufacturing issues associated with PAT-SM6, and has ongoing business development efforts to progress the development of its other IgM assets on a risk sharing basis.

### Subsequent to Quarter

#### *Website*

In September Patrys launched a new website to detail the Company's operations and assets as well as its policies and governance documents.

#### *Change of Principal Place of Business*

As part of the ongoing operational efficiency drive during October Patrys changed its Principal Place of Business to the Company's Registered Office being Level 4, 100 Albert Road, South Melbourne, Victoria, 3205.

#### *Change to Managing Director's Incentive*

The Board has agreed to amend the Long Term Incentives for Dr James Campbell from a Loan Share Plan Issue to an options Issue. This change, from Loan Share Plan incentives to Options is simpler for the Company to administer and has no material impact on the financial position or performance of

Level 4, 100 Albert Road, South Melbourne, Victoria, 3205 Australia  
Phone: +61 (0) 3 96703273  
ABN: 97 123 055 363



the Company. Dr Campbell and the Board have agreed to this change subject to shareholder approval at the upcoming Annual General Meeting.

An Appendix 4C accompanies this announcement.

For and on behalf of the Board of Patrys Limited,

James Campbell  
Managing Director  
[jcampbell@patrys.com](mailto:jcampbell@patrys.com)

### **About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Patrys Limited

**ABN**

97 123 055 363

**Quarter ended ("current quarter")**

30 September 2016

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	335	335
1.2 Payments for		
(a) research and development	(260)	(260)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(98)	(98)
(f) administration and corporate costs	(143)	(143)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	30	30
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(136)</b>	<b>(136)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(3)	(3)
(b) businesses (see item 10)	-	-
(c) investments	-	-

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
(d) intellectual property	(36)	(36)
(e) other non-current assets	-	-
<b>2.2 Proceeds from disposal of:</b>		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
<b>2.3 Cash flows from loans to other entities</b>	-	-
<b>2.4 Dividends received (see note 3)</b>	-	-
<b>2.5 Other (provide details if material)</b>	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(39)</b>	<b>(39)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	3,213	3,213
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(136)	(136)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(39)	(39)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	(25)	(25)
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>3,013</b>	<b>3,013</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	1,513	1,213
5.2	Call deposits	1,500	2,000
5.3	Bank overdrafts	-	
5.4	Other	-	
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3,013</b>	<b>3,213</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter \$A'000</b>
103
-

Cash payments to directors for executive director salaries, non-executive director fees and consulting services for the quarter.

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

<b>Current quarter \$A'000</b>
-
-

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		


--

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	394
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	102
9.6 Administration and corporate costs	106
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>602</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: .....  ..... Date: 28.10.2016  
(Company secretary)

Print name: Melanie Leydin

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.